What is Optrex Bacterial Conjunctivitis 1%?
Optrex Bacterial Conjunctivitis 1% belongs to the family of medicines called antibiotics. Optrex Bacterial Conjunctivitis 1% ophthalmic preparations are used to treat infections of the eye. Optrex Bacterial Conjunctivitis 1% may be given alone or with other medicines that are taken by mouth for eye infections.
Optrex Bacterial Conjunctivitis 1% is available only with your doctor's prescription.
Optrex Bacterial Conjunctivitis 1% indications
Optrex Bacterial Conjunctivitis 1% should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to Optrex Bacterial Conjunctivitis 1%.
Optrex Bacterial Conjunctivitis 1%, 1% (Optrex Bacterial Conjunctivitis 1% Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by Optrex Bacterial Conjunctivitis 1%-susceptible organisms.
The particular antiinfective drug in this product is active against the following common bacterial eye pathogens:
Staphylococcus aureus
Streptococcus, including Streptococcus pneumoniae
Escherichia coli
Haemophilus influenzae
Klebsiella/Enterobacter species
Moraxella lucunata
(Morax-Axenfeld bacillus)
Neisseria species
This product does not provide adequate coverage against:
Pseudomonas aeruginosa
Serratia marcescens
How should I use Optrex Bacterial Conjunctivitis 1%?
Use Optrex Bacterial Conjunctivitis 1% as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Optrex Bacterial Conjunctivitis 1% is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Optrex Bacterial Conjunctivitis 1% at home, carefully follow the injection procedures taught to you by your health care provider.
- If Optrex Bacterial Conjunctivitis 1% contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.
- To clear up your infection completely, continue using Optrex Bacterial Conjunctivitis 1% for the full course of treatment even if you feel better in a few days.
- Keep this product, as well as syringes and needles, out of the reach of children. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.
- If you miss a dose of Optrex Bacterial Conjunctivitis 1%, use it as soon as possible. Then use your doses at evenly spaced times as directed by your doctor. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Optrex Bacterial Conjunctivitis 1%.
Uses of Optrex Bacterial Conjunctivitis 1% in details
Use: Labeled Indications
Serious infections: Treatment of serious infections, including cystic fibrosis exacerbations, bacterial meningitis, and bacteremia, caused by Chlamydiaceae, Haemophilus influenzae, Rickettsia, Salmonella spp. (acute infections), and other organisms when other less toxic agents are ineffective or contraindicated.
Guideline recommendations: Optrex Bacterial Conjunctivitis 1% may be considered for use as an alternative agent to doxycycline in the treatment of tickborne rickettsial diseases (eg, Rocky Mountain spotted fever [RMSF]); however, epidemiologic studies suggest that Optrex Bacterial Conjunctivitis 1%-treated patients with RMSF are at a higher risk of death compared to tetracycline-treated patients. In addition, Optrex Bacterial Conjunctivitis 1% is not effective in the treatment of human ehrlichiosis or anaplasmosis, therefore, use with caution in the empiric treatment of tickborne rickettsial diseases (CDC [Biggs 2016]).
Optrex Bacterial Conjunctivitis 1% description
Each 100 g contains Chloramphenicol 1 g.
Optrex Bacterial Conjunctivitis 1% dosage
Optrex Bacterial Conjunctivitis 1% Dosage
Generic name: Optrex Bacterial Conjunctivitis 1%
Dosage form: ophthalmic ointment
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
A small amount of ointment placed in the lower conjunctival sac every three hours, or more frequently if deemed advisable by the prescribing physician. Administration should be continued day and night the first 48 hours, after which the interval between applications may be increased. Treatment should be continued for at least 48 hours after the eye appears normal.
More about Chloromycetin Ophthalmic (Optrex Bacterial Conjunctivitis 1% ophthalmic)
- Side Effects
- Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews · Be the first to review/rate this drug
Consumer resources
- Other brands: Ocu-Chlor, Chloroptic, AK-Chlor
Professional resources
- Optrex Bacterial Conjunctivitis 1% (FDA)
Other formulations
- Chloromycetin
- Chloromycetin Sodium Succinate
Optrex Bacterial Conjunctivitis 1% interactions
Alcohol (Ethyl): Optrex Bacterial Conjunctivitis 1% (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). Monitor therapy
Barbiturates: Optrex Bacterial Conjunctivitis 1% (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Optrex Bacterial Conjunctivitis 1% (Systemic). Monitor therapy
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Carbocisteine: Optrex Bacterial Conjunctivitis 1% (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, Optrex Bacterial Conjunctivitis 1% may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. Monitor therapy
CefTAZidime: Optrex Bacterial Conjunctivitis 1% (Systemic) may diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Consider therapy modification
Optrex Bacterial Conjunctivitis 1% (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Avoid combination
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy
CycloSPORINE (Systemic): Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent Optrex Bacterial Conjunctivitis 1%. Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of Optrex Bacterial Conjunctivitis 1%. Consider therapy modification
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Consider therapy modification
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination
Fosphenytoin: May decrease the serum concentration of Optrex Bacterial Conjunctivitis 1% (Systemic). Fosphenytoin may increase the serum concentration of Optrex Bacterial Conjunctivitis 1% (Systemic). Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of Fosphenytoin. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Mesalamine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Phenytoin: May decrease the serum concentration of Optrex Bacterial Conjunctivitis 1% (Systemic). Phenytoin may increase the serum concentration of Optrex Bacterial Conjunctivitis 1% (Systemic). Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of Phenytoin. Monitor therapy
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
RifAMPin: May increase the metabolism of Optrex Bacterial Conjunctivitis 1% (Systemic). Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Sulfonylureas: Optrex Bacterial Conjunctivitis 1% (Systemic) may decrease the metabolism of Sulfonylureas. Monitor therapy
Tacrolimus (Systemic): Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent Optrex Bacterial Conjunctivitis 1%. Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of Optrex Bacterial Conjunctivitis 1%. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Vitamin B12: Optrex Bacterial Conjunctivitis 1% (Systemic) may diminish the therapeutic effect of Vitamin B12. Monitor therapy
Vitamin K Antagonists (eg, warfarin): Optrex Bacterial Conjunctivitis 1% (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of Vitamin K Antagonists. Monitor therapy
Voriconazole: Optrex Bacterial Conjunctivitis 1% (Systemic) may increase the serum concentration of Voriconazole. Monitor therapy
Optrex Bacterial Conjunctivitis 1% side effects
See also:
What are the possible side effects of Optrex Bacterial Conjunctivitis 1%?
Applies to Optrex Bacterial Conjunctivitis 1%: capsule, powder for solution, suspension
In addition to its needed effects, some unwanted effects may be caused by Optrex Bacterial Conjunctivitis 1% (the active ingredient contained in Optrex Bacterial Conjunctivitis 1%). In the event that any of these side effects do occur, they may require medical attention.
Stop taking Optrex Bacterial Conjunctivitis 1% and get emergency help immediately if any of the following effects occur:
Rare - in babies only
- Bloated stomach
- drowsiness
- gray skin color
- low body temperature
- uneven breathing
- unresponsiveness
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Optrex Bacterial Conjunctivitis 1%:
Less common:
- Pale skin
- sore throat and fever
- unusual bleeding or bruising
- unusual tiredness or weakness (the above side effects may also occur up to weeks or months after you Stop taking Optrex Bacterial Conjunctivitis 1%)
- Confusion, delirium, or headache
- eye pain, blurred vision, or loss of vision
- numbness, tingling, burning pain, or weakness in the hands or feet
- skin rash, fever, or difficulty in breathing
Minor Side Effects
Some of the side effects that can occur with Optrex Bacterial Conjunctivitis 1% may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Less common:
- Diarrhea
- nausea or vomiting
Optrex Bacterial Conjunctivitis 1% contraindications
See also:
What is the most important information I should know about Optrex Bacterial Conjunctivitis 1%?
Optrex Bacterial Conjunctivitis 1% Lotion is contraindicated for premature neonates because their skin may be more permeable than full term infants and their liver enzymes may not be sufficiently developed. It is also contraindicated for patients with Norwegian (crusted) scabies due to possible increased absorption. It is also contraindicated for patients with known seizure disorders and for individuals with a known sensitivity to the product or any of its components.
Active ingredient matches for Optrex Bacterial Conjunctivitis 1%:
Chloramphenicol in United Kingdom.
List of Optrex Bacterial Conjunctivitis 1% substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Optrex Infected Eyes (United Kingdom) | |
| Orbachlor 0.5% (Peru) | |
| Orichlor | |
| Orichlor 30 ml Syrup (Orison Pharmaceuticals) | $ 0.03 |
| Osochlor | |
| Osochlor 500 mg Tablet (Osho Pharma Pvt.Ltd.) | $ 0.05 |
| Osochlor 250 mg Tablet (Osho Pharma Pvt.Ltd.) | $ 0.03 |
| Otachron | |
| Otiden (India) | |
| Otiden Chloramphenicol 5 %, Beclomethasone dipropionate0.025 %, Clotrimazole 1 %, Lignocaine 2 %. EAR-DPS / 10ml (BMW Pharmaco India Pvt Ltd) | $ 0.36 |
| 10ml (BMW Pharmaco India Pvt Ltd) | $ 0.36 |
| Otiden 10 ml Drop (BMW Pharmaco India Pvt Ltd) | $ 0.04 |
| Otiden Chloramphenicol 5 %, beclomethasone dipropionate0.025 %, clotrimazole 1 %, lignocaine hydrochloride 2 %. EAR DPS / 10ml (BMW Pharmaco India Pvt Ltd) | $ 0.46 |
| OTIDEN ear drops 10ml (BMW Pharmaco India Pvt Ltd) | $ 0.46 |
| Otophen | |
| Otophenicol (Ethiopia) | |
| Otophenicol 5% (Egypt) | |
| Otosym (India) | |
| Otosym Chloramphenicol 5 % w/v, Beclomethasone dipropionate0.025 % w/v, Clotrimazole 1 %w/v, Lignocaine hydrochloride2 % w/v. EAR-DPS / 5ml (Symbiosis Labs (P) Ltd.) | $ 0.36 |
| 5ml (Symbiosis Labs (P) Ltd.) | $ 0.36 |
| Otosym Ear 5 ml Drop (Symbiosis Labs (P) Ltd.) | $ 0.07 |
| Otosym Chloramphenicol 5 % w/v, beclomethasone dipropionate0.025 % w/v, clotrimazole 1 %w/v, lignocaine hydrochloride2 % w/v. EAR DPS / 5ml (Symbiosis Labs (P) Ltd.) | $ 0.36 |
| OTOSYM ear drops 5ml (Symbiosis Labs (P) Ltd.) | $ 0.36 |
| Ototic | |
| Ototic Ear 5 ml Drop (Zest Pharma) | $ 0.43 |
| Owadziak | |
| Palcol (Mexico) | |
| Palmiclor (Mexico) | |
| Palmicol (Indonesia) | |
| Palmicol 250 mg x 10 x 10's (Cheplapharm) | |
| Palmicol 125 mg/5 mL x 60 mL (Cheplapharm) | |
| Palmifer (Mexico) | |
| Palmisol (Mexico) | |
| Palmitato de Chloromycetin (Mexico) | |
| Suspension; Oral; Chloramphenicol Palmitate 312.5 mg / ml | |
| Pantofenicol (Spain) | |
| Pantovernil | |
| Paraxin (Colombia, Ecuador, Ethiopia, India) | |
| Capsule; Oral; Chloramphenicol; Chloramphenicol Palmitate (AHPL) | |
| Injectable; Injection; Chloramphenicol; Chloramphenicol Palmitate (AHPL) | |
| Drops; Oral; Chloramphenicol; Chloramphenicol Palmitate (AHPL) | |
| Ointment; Topical; Chloramphenicol; Chloramphenicol Palmitate (AHPL) | |
| PARAXIN Capsule/ Tablet / 250mg / 10 units (AHPL) | $ 0.55 |
| PARAXIN Capsule/ Tablet / 500mg / 6 units (AHPL) | $ 0.63 |
| Paraxin 250mg SC-TAB / 10 (AHPL) | $ 0.55 |
| Paraxin 250mg CAP / 10 (AHPL) | $ 0.55 |
| Paraxin 500mg CAP / 6 (AHPL) | $ 0.63 |
| Paraxin 125mg/5mL SUSP / 100ml (AHPL) | $ 0.78 |
| Paraxin 1g INJ / 1 (AHPL) | $ 0.31 |
| 250 mg x 10's (AHPL) | $ 0.55 |
See 1906 substitutes for Optrex Bacterial Conjunctivitis 1% | |
References
- DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "chloramphenicol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "chloramphenicol". http://www.drugbank.ca/drugs/DB00446 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Optrex Bacterial Conjunctivitis 1% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Optrex Bacterial Conjunctivitis 1%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
